Am Heart J Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: Impact on Adverse Outcomes in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

[tetano]

Am Heart J


. 2020 May 13;226:49-59.
doi: 10.1016/j.ahj.2020.05.002. Online ahead of print.
Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: Impact on Adverse Outcomes in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial


Renato D Lopes ¹ , Ariane Vieira Scarlatelli Macedo ² , Pedro Gabriel Melo de Barros E Silva ³ , Renata Junqueira Moll-Bernardes ⁴ , Andre Feldman ⁵ , Guilherme D'Andr?a Saba Arruda ⁵ , Andrea Silvestre de Souza ⁶ , Denilson Campos de Albuquerque ⁷ , Lilian Mazza ³ , Mayara Fraga Santos ⁴ , Natalia Zerbinatti Salvador ⁴ , C Michael Gibson ⁸ , Christopher B Granger ⁹ , John H Alexander ⁹ , Olga Ferreira de Souza ⁵ , BRACE CORONA investigators



Affiliations

• PMID: 32502882
• PMCID: PMC7219415
• DOI: 10.1016/j.ahj.2020.05.002

Free PMC article

Abstract

Angiotensin-converting enzyme-2 (ACE2) expression may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs). Because renin-angiotensin system blockers increase levels of ACE2, a protein that facilitates coronavirus entry into cells, there is concern that these drugs could increase the risk of developing a severe and fatal form of COVID-19. The impact of discontinuing ACEI and ARBs in patients with COVID-19 remains uncertain. DESIGN: BRACE CORONA is a pragmatic, multicenter, randomized, phase IV, clinical trial that aims to enroll around 500 participants at 34 sites in Brazil. Participants will be identified from an ongoing national registry of suspected and confirmed cases of COVID-19. Eligible patients using renin-angiotensin system blockers (ACEI/ARBs) with a confirmed diagnosis of COVID-19 will be randomized to a strategy of continued ACEI/ARB treatment versus temporary discontinuation for 30 days. The primary outcome is the median days alive and out of the hospital at 30 days. Secondary outcomes include progression of COVID-19 disease, all-cause mortality, death from cardiovascular causes, myocardial infarction, stroke, transient ischemic attack, new or worsening heart failure, myocarditis, pericarditis, arrhythmias, thromboembolic events, hypertensive crisis, respiratory failure, hemodynamic decompensation, sepsis, renal failure, and troponin, B-type natriuretic peptide (BNP), N-terminal-proBNP, and D-dimer levels. SUMMARY: BRACE CORONA will evaluate whether the strategy of continued ACEI/ARB therapy compared with temporary discontinuation of these drugs impacts clinical outcomes among patients with COVID-19.